He Zhenyu, Kee Kehkooi
Center for Stem Cell Biology and Regenerative Medicine, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, China.
Methods Mol Biol. 2017;1498:153-162. doi: 10.1007/978-1-4939-6472-7_10.
Gene targeting and editing is an essential tool for both basic research and clinical application such as gene therapy. Several endonucleases have been invented to fulfill these purposes, including zinc finger nucleases, TALEN, and CRISPR/Cas9. Although all of these systems can target DNA sequence with high efficiency, they also exert off-target effects and genotoxicity. The off-target effects might not hinder their usage in animal models because the correctly targeted cells can be selected for further studies. However, the off-target effects could cause mutations which may be damaging or cancerous to the patients. In this chapter, we describe a genome-editing nuclease method which relies on modifying specific amino acids on a monomeric endonuclease, I-SceI, to recognize a targeted sequence in the human genome. This nuclease is small in size and shows a much lower genotoxicity compared to other nucleases including CRISPR/Cas9.
基因靶向和编辑是基础研究和临床应用(如基因治疗)的重要工具。为实现这些目的,人们发明了几种核酸内切酶,包括锌指核酸酶、转录激活因子样效应物核酸酶(TALEN)和规律成簇间隔短回文重复序列/CRISPR相关蛋白9(CRISPR/Cas9)。尽管所有这些系统都能高效靶向DNA序列,但它们也会产生脱靶效应和基因毒性。脱靶效应可能不会妨碍它们在动物模型中的应用,因为可以选择正确靶向的细胞进行进一步研究。然而,脱靶效应可能会导致突变,这对患者可能是有害的或致癌的。在本章中,我们描述了一种基因组编辑核酸酶方法,该方法依赖于修饰单体核酸内切酶I-SceI上的特定氨基酸,以识别人类基因组中的靶向序列。这种核酸酶体积小,与包括CRISPR/Cas9在内的其他核酸酶相比,其基因毒性要低得多。